BRISBANE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classⁱ targeted and immune-mediated therapeutics to fight cancer, today announced that management will participate in the following upcoming investor conferences:

• TD Cowen's 5th Annual Oncology Innovation Summit – Fireside chat on Wednesday, May 29, 2024 at 2:00 p.m. ET
   
• Jefferies Global Healthcare Conference – Presentation on Wednesday, June 5, 2024 at 4:00 p.m. ET

To access the live or archived recording of the discussions, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor & Media Contacts

Sylvia Wheeler
Wheelhouse Life Science Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.

Aljanae Reynolds
Wheelhouse Life Science Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.